Company: DAWN
Filing Date: 2025-04-11
Form Type: DEF 14A
Source: 0001140361-25-013462
Chunk: 49

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: DEF 14A
Chunk 49
---
 summarized in the table below.

| Executive        |     | Target Bonus 
          ($) |     | Actual Bonus 
          ($) |
| Jeremy Bender    |     |     $408,000 |     |     $501,800 |
| Charles York, II |     |     $243,000 |     |     $299,400 |
| Samuel Blackman  |     |     $237,000 |     |     $291,700 |
| Adam Dubow       |     |     $182,000 |     |     $223,900 |

Long-Term Equity Incentive Awards Our equity awards serve as a long-term retention tool, encouraging executives to remain with Day One and build value over the long term. The NEOs’ equity compensation is delivered in the form of stock options (50%) and RSUs (50%) allocated based on fair value using 30-day trading average as of December 31, 2023 calculated in accordance with ASC 718. The Compensation Committee selected these equity vehicles and allocations to place an equal emphasis on stock options, which it views as inherently performance-based. In making this determination, it also considered that use of these equity vehicles is generally consistent with compensation practices among our peer group. All equity grants are subject to vesting over a 4-year period providing further retentive value. Target Equity Grants for the Performance Period Beginning in 2024 In January 2024, the Compensation Committee granted the following equity awards to the NEOs, which fell between the 30 thand 80 thpercentiles of our peer group:

| Executive        |     | Stock Options 
           (#) |     |    RSUs 
     (#) |     | Total Target Equity Value(1) |
| Jeremy Bender    |     |       286,000 |     | 187,000 |     |                   $4,871,000 |
| Charles York, II |     |       162,000 |     | 106,000 |     |                   $2,760,000 |
| Samuel Blackman  |     |       148,000 |     |  97,000 |     |                   $2,523,000 |
| Adam Dubow       |     |        90,000 |     |  59,000 |     |                   $1,535,000 |

| (1) | The number of stock options and RSUs delivered to our NEOs is calculated using the DAWN Nasdaq closing price 30-day trailing average as of